Skip to main content

New project to explore effective of vaping on respiratory system

The benefits and harms of vaping for long term respiratory health will be the focus of a new research project, thanks to a funding award of £1.46m by the Medical Research Council (MRC).

Building on internationally recognised work in e-cigarette studies at BHP founder-members the University of Birmingham, the EVALUATE study aims to address unanswered questions about the effect of long-term vaping on the respiratory system by conducting a four-year cohort study.

Dr Aaron Scott, Associate Professor in Respiratory Science at the University of Birmingham and Chief Investigator of EVALUATE said: “We will study how vaping affects important airway immune cells and the epithelial cells which line the insides of the lung. Since these cell types play a critical role in the development of smoking-related lung diseases, these changes will provide clear insight into vaping’s on lung health”

“This study will provide critical data needed to understand the safety of vaping as a short-term smoking cessation strategy and in longer-term usage so people can make an informed personal choice”

David Thickett, Professor of Respiratory Medicine at the University of Birmingham and Clinical lead of University Hospitals Birmingham’s staff smoking cessation service said: “The EVALUATE study will investigate changes to immune and lung cell health following vaping. Supported by the NIHR Birmingham Biomedical Research Centre, the multi-faceted study will also investigate how vaping changes the human microbiome after smoking cessation. For the trillions of microorganisms that live on and in the human body, environmental factors can affect the delicate balance of microbiomes and can impact health if disrupted.”

Dr Dhruv Parekh, Associate Professor in Respiratory Medicine and Director of the University Hospitals Birmingham Clinical Research Facility said: “Studying immune cells from the blood (indirect effects) and from the airways (direct effects) by bronchoscopy, allows us to get a complete picture of how the airways are affected by vaping. This important study will be delivered through our NIHR Clinical Research Facility which is integral to the delivery of this work.”

Dr Mike Cox, Assistant Professor Respiratory Microbiome at the University of Birmingham said: “Smoking can drastically alter microorganisms in our bodies, particularly in the airways. This project will allow us to uncover how vaping impacts this balance and map out how this changes over time.”

Studying toxicants in the airways

Previous work from Dr Scott’s lab at the University of Birmingham has shown that toxicants within e-cigarette vapour, formed by the breakdown of e-liquid, can negatively impact important immune cells, independently to the effects of nicotine. Some of these toxic components of e-cigarette vapour are also found in cigarette smoke. We know this could harm our airways, but this is difficult to sample and measure.

Professor Luis Mur at Aberystwyth University will lead the investigation into the accumulation of toxicants within the airways after vaping. Professor Mur said: “Using our cutting-edge mass spectroscopy platforms, we can monitor how toxicants in the airways change as people move from smoking to vaping. Combined with data on immune cell function, this interdisciplinary approach will give us a powerful insight into the true nature of e-cigarette exposure on the airways.”

This new study will also run alongside a complementary clinical trial, ECAL and linked EME mechanism study, which is examining the impact of vaping in patients with chronic obstructive pulmonary disease (COPD).

The research team will begin recruiting for the EVALUATE study in the Autumn of 2025.

UK healthcare leader Richard Meddings to chair Birmingham Health Partners 

Richard Meddings CBE, the former chair of NHS England, has been appointed Chair of Birmingham Health Partners – signifying the importance, ambition and leadership of the second city’s NHS-university partnership. Richard will take up his role from October 1st 2025. 

Richard completed a three-year term at NHS England until March 2025. During his tenure, he oversaw the reorganisation which led to NHS Improvement, NHS-X and Health Education England merging into NHS England, which reduced costs and placed more funding directly into patient care. Additionally, the first NHS Long Term Workforce Plan was delivered and Integrated Care Boards formally established.  

Alongside his NHS England role, Richard was a non-executive director at Genomics England – established by the UK Government to bring genomic medicine into routine NHS care and transform diagnosis and treatment of cancer and rare conditions. 

Originally from Wolverhampton, Richard moved into healthcare leadership after a 30-year career in financial services and banking, where his senior executive roles included Group Executive Director at Standard Chartered, following finance director roles at the Woolwich and Barclays. He has served in non-executive board roles for numerous organisations including Legal & General, Deutsche Bank, Credit Suisse and TSB Bank, as well as seven years on the Board of HM Treasury.  

Commenting on his appointment, Richard said: “Today’s NHS is a remarkable machine, providing record levels of care, and it has been humbling and inspiring to witness that front-line work in action. In tandem, research innovations are coming thick and fast which will enable us to be more proactive with patients, address capacity issues and harness the power of new technology. Nowhere are these opportunities greater than in my native West Midlands, making it a very exciting time to join BHP.” 

Professor Sir Bruce Keogh, Chair of Birmingham Women’s and Children’s NHS Foundation Trust, said: “Richard brings gravitas, wider connections and additional vision to Birmingham Health Partners. BHP’s member organisations will benefit greatly from his deep understanding of the NHS and the promise that Birmingham’s national genomics programme offers to our population, the regional life science industry, and the future of medicine.” 

Dame Yve Buckland, Chair of University Hospitals Birmingham NHS Foundation Trust, said: “Richard’s leadership experience, skills and insights will be invaluable to our important collaboration and the opportunity we have to advance new treatments, diagnostics, and technologies to improve the health and care of our communities – which include some of the most challenged in the country.” 

Sir David Nicholson, Chair of Sandwell and West Birmingham NHS Trust, said: “It is tremendous to welcome Richard back to the West Midlands. Birmingham is a UK leading centre hosting one of the most substantial Government investments in research via the National Institute for Health and Care Research (NIHR) amongst others. Our work in health data, addressing health inequalities and optimising clinical trials is already improving healthcare. It is an exciting time across our partnership.”  

Professor Neil Hanley, Executive Director of Birmingham Health Partners and Pro-Vice Chancellor and Head of the College of Medicine & Health at the University of Birmingham: ‘I am absolutely delighted we have persuaded Richard to become our next chair of Birmingham Health Partners. Combining business and financial acumen with his experience at the helm of NHS England, he will give us a unique perspective on the opportunities presented by the NHS 10-year plan and Life Sciences Sector Plan. We’re delighted to have him join our Board.” 

BHP, established in 2015, is a strategic alliance between nine University and NHS members who collaborate to deliver groundbreaking translational research, world-class education and training, and the highest quality patient care. 

NIHR Clinical Research Facility celebrates year of growth and success

Birmingham’s NIHR/Wellcome Trust Clinical Research Facility (CRF) has celebrated yet another successful year, with thousands of patients and volunteers taking part in pioneering studies that are shaping the future of medicine.

Established in 2001, the CRF provides a high-quality environment for experimental and early-phase research across all age groups.

Spanning two of Birmingham Health Partners’ NHS member Trusts, the CRF runs its adult unit from Queen Elizabeth Hospital Birmingham (QEHB), part of University Hospitals Birmingham NHS Foundation Trust, and its paediatric unit from Birmingham Children’s Hospital, part of Birmingham Women’s and Children’s NHS Foundation Trust (BWC).

Between 31 March 2024 and 1 April 2025, the CRF supported 409 active studies – 334 at UHB and 75 at BWC – involving 13,503 patient visits and the recruitment of 2,514 participants.

The facility has seen a particular growth in Advanced Therapy Investigational Medicinal Product (ATIMP) studies, which explore innovative treatments based on genes, cells, or tissues. It has also expanded work in maternal health, mental health and neonatal research, as well as opening studies in new disease areas.

Collaboration is central to the CRF’s approach, with almost half of its studies (48%) co-delivered in partnership with other NIHR infrastructure, including the Birmingham Biomedical Research Centre. This way of working ensures expertise and resources are shared to maximise patient benefit and research impact.

The year also saw significant investment, with over £4 million secured by the facility to open a new clinical research unit in the MIDRU building at Heartlands Hospital, as well as new laboratory and endoscopy equipment purchased for both QEHB and Good Hope Hospital.

Patients themselves have spoken warmly of their experience at the CRF, with recent feedback including: “Every week has been a pleasure visiting the Wellcome Research Centre”, “All staff were extremely friendly, supportive and knowledgeable” and “They are kind and thoughtful, giving you all the information you need to feel comfortable”.

Jo Gray, Head of Research and Development Operations, said: “I’m incredibly proud of all our colleagues in the Clinical Research Facility for their dedication and hard work in delivering patient-centred research across a wide range of studies and disease areas. Their impact on patients is evident in the feedback we receive, and we look forward to building on last year’s successes through continued collaboration with our industry partners.”

Members of the CRF team gathered to celebrate another successful year

Birmingham academic appointed Clinical Lead of new NIHR network

The National Institute for Health and Care Research (NIHR) has awarded £6.5 million, funded jointly through a public-private partnership with the pharmaceutical industry, to establish a UK-wide Commercial Research Delivery Centre (CRDC) Network. The Network is hosted by University Hospitals of Leicester NHS Trust (UHL), with Birmingham Health Partners’ Managing Director Professor Lorraine Harper as its Clinical Lead, and will commence formally on 1 September 2025.

The new Network will provide strategic coordination of all 21 CRDCs across the the UK. It will play a key role in building research capacity, streamlining the interface between industry and the UK clinical trials delivery infrastructure, and enhancing efficiency to deliver commercial clinical research through harmonised processes, in line with the Government’s call to turbocharge medical research earlier this year.

The Network will:

  • Provide strategic leadership and national coordination across the 21 CRDCs across the UK
  • Offer a central point of contact for industry sponsors
  • Facilitate study feasibility, placement and setup across the UK
  • Foster collaboration with regulators, wider NIHR and UK-wide delivery infrastructure, and other key stakeholders to advance UK Clinical Research Delivery
  • Support workforce development, inclusion, and public involvement
  • Facilitate the integration of the Primary Care CRDCs (PC-CRDCs) in England in autumn 2025, adopting them into the Network

By aligning CRDC efforts and offering a cohesive offer to industry, the Network will ensure that the CRDCs deliver against industry expectations for faster, more efficient set up and delivery of commercial research in the UK.

Lorraine Harper, Professor of Nephrology at the University of Birmingham and Managing Director of Birmingham Health Partners, is the Director of the Central and North West Midlands CRDC and has been appointed Clinical Lead of the new Network. She said: “The vision of the Network is to ensure equitable access, diverse recruitment and a much more efficient model of trial delivery, improving NHS and patient access to trials. With Birmingham Health Partners already leading a regional programme to reduce bureaucracy in clinical trials, and BHP member Birmingham Women’s and Children’s Hospitals hosting the Central and North West Midlands CRDC, this is an exciting opportunity to align all our work and deliver a ‘gold standard’ for commercial clinical trials.”

BHP founding member Birmingham Women’s and Children’s Hospitals NHS Foundation Trust hosts the £7m Central and West North Midlands (C&NWM) CRDC, working closely with regional partners Midlands Partnership University NHS Foundation Trust – host of Staffordshire and Shropshire, Telford and Wrekin Health Research Partnership (SSHERPA) – and the Black Country Provider Collaborative.

The C&NWM region, home to 4.2 million people, includes many of the UK’s most economically deprived communities who face significant health inequalities and higher rates of serious illness. The CRDC will focus on addressing these inequities by increasing access to clinical trials for patients who have the greatest need – dovetailing with BHP’s strategic focus on addressing health inequalities and giving greater opportunities for residents to participate in research.

Professor Melanie Davies, Professor of Diabetes Medicine at the University of Leicester and Honorary Consultant Diabetologist for University Hospitals of Leicester NHS Trust, and Director of the CRDC Network, said: “We are really proud that University Hospitals of Leicester NHS Trust has been awarded this funding to host this federated CRDC Network across the four nations of the UK. We are fully committed to working with our partners across the UK to deliver faster, more efficient set up and delivery of commercial research. We want to drive increased investment from industry and enable even more people to take part in studies that can lead to the future approval of new medicines and devices for the benefit of patients in the UK.”

Dr Maria Koufali, NIHR Life Sciences Industry Director, said: “The UK CRDC Network is a critical part of our national effort to transform UK clinical research delivery. By streamlining trial set-up and expanding access into community and underserved settings, it will help make the UK one of the most attractive destinations globally for commercial research. This means faster access to innovative treatments for patients, greater investment in the NHS and a stronger life sciences sector that boosts the health and wealth of the nation.”

Pardeep Janjua and Carlos Chan take home summer BHP People awards

July’s BHP People awards have been awarded to Pardeep Janjua, Research Data and Systems Officer at Sandwell and West Birmingham Hospitals (SWB) and Carlos Chan, Research Development Coordinator at the Royal Orthopaedic Hospital (ROH).

Our reward and recognition scheme is designed to spotlight our colleagues who play a vital role in the success of research studies and clinical trials, and whose work is integral to groundbreaking scientific endeavours.

“Pardeep has presented this work at two international conferences and it has also earnt him an internal Trust award. He has been upscaling this work across the Black Country and is now in discussions to extend beyond.

“These data sets and report not only aid in decision making for individual projects and researchers but have enabled us to baseline and benchmark departments to enable new initiatives.”

Nominating Carlos, the ROH’s Head of Research, Audit and Development Gareth Stephens, said: “Carlos came to R&D at ROH after relocating his family from Hong Kong to the UK. He started with us in a Band 2 administrative role; however, his project management and IT skills were very quickly apparent. These skills have seen him successfully climb the ladder within R&D, initially as a Data Manager and now as a Research Development Coordinator, within our Governance team.

“Carlos has an unrivalled work ethic, diligence and attention to detail that makes him ideally suited to research. Furthermore, his courteous manner, ‘can-do’ attitude and positivity make him a popular and supportive member of staff. Carlos has significantly improved our data capture and analysis capabilities, especially concerning study set up times. As a result of his work, we are seeing our processes become more efficient and set-up times reducing. We have no doubts that Carlos will continue to develop within the coming years.”

By championing individuals including research nurses, statisticians, pharmacists and many others, BHP People also highlights the incredible diversity of careers in research and the essential contributions that these professionals make. As well as celebrating individual excellence, the initiative reflects the shared dedication of our diverse partner organisations to driving collaborative research.


Meet our previous winners

BHP People – “one team, one goal”

Carlos Chan, Research Development Coordinator at the Royal Orthopaedic Hospital, is the Trust’s first recipient of the BHP People recognition award.

We spoke to Carlos about his rapid progression from administrator to integral member of the ROH’s growing research team.

Q: Can you briefly run us through your career so far and how you came to work at ROH?

CC: My career began at a multinational nutrition science company in Hong Kong, where I worked as a brand manager and was heavily involved in new product development and commercial research. When I relocated to the UK I was keen to pursue a career in research, as it aligned closely with my personal values – especially the goal of contributing to better health for future generations. That’s when I had the opportunity to join the ROH Research Team.

I initially started as a band 2 administrator, which gave me invaluable insight into how the Trust operates and allowed me to build strong relationships across departments. My curiosity and desire to contribute more deeply led to a promotion to Data Manager where, with the support of a fantastic team, we significantly improved study delivery – streamlining referrals and communication for the ICONIC osteosarcoma study and hitting recruitment targets for the RADICAL pain management trial. We also achieved the highest response rate in the West Midlands for the 2023 NIHR Participant in Research Experience Survey (PRES).

I’m now working as a Research Development Coordinator, where I draw on my project management and liaison skills. Thanks to the collaborative culture and my earlier experience in delivery, we’ve streamlined processes and reduced setup times. It’s been a journey full of support and inclusion, and I’m excited for what’s ahead!

Q: In your current role, what are some of the tasks and duties you’re involved in most frequently?

CC: I’m responsible for coordinating research projects from the feasibility stage through to activation, and then managing amendments throughout the study’s life cycle.

I work closely with internal and external partners, including trial units, Principal Investigators, clinicians, research nurses, data managers, and pharmacy technicians. I also liaise with national bodies like the NIHR, HRA, and HSCNI to resolve governance queries.

My duties include performing local governance checks, securing cost approvals, managing risk assessments, and finalising contracts. This ensures that our site is ready and capable of opening each study.

Q: Have you experienced any particular challenges in your role, and how have you overcome them?

CC: Like any collaborative environment, we do encounter challenges – particularly when coordinating across departments or working through complex processes. When this happens, I always return to the principle of “one team, one goal.” I try to clearly identify our shared objective and assess what’s realistically achievable based on the resources available. We then openly discuss the pros and cons of different approaches. This collaborative decision-making ensures we move forward with the most effective solution, even if it’s not perfect for everyone involved.

Q: You’ve played a major role in improving data capture and reducing study set-up times – can you tell us more about the changes you introduced and the impact they’ve had?

CC: When I stepped into my current role, I noticed an opportunity to improve our study set-up tracking. I integrated our existing local governance processes into a custom-programmed Gantt chart which allows us to track every milestone and subtask, assign responsibilities, and monitor lead times. It has dramatically improved our visibility into each study’s progress. Additionally, we created a performance dashboard using PowerBI. This automation reduced the time required for reporting from several hours to just a few minutes. These tools have not only streamlined workflows but also enabled us to spot delays early and proactively address them – leading to faster, more efficient study setups.

Q: Can you tell us about some of the studies (past or present) that you’ve found particularly rewarding to be part of?

CC: One standout project is the ICONIC study, a UK-wide osteosarcoma research initiative which collects clinical and biological data to enhance our understanding of this rare cancer. As a surgical site without chemotherapy services, we had many referrals and patient transfers, which added complexity. Maintaining data integrity and a positive patient experience across sites was a challenge we tackled through strong collaboration with the trial unit and teams across the UK. The study is now at the end of recruitment, and I’m incredibly proud of our contribution.

More recently, we launched the FORENSIC trial, sponsored by the University of Oxford and led locally by Professor Adrian Gardner. It investigates whether lumbar fusion surgery is more effective than conservative care for persistent lower back pain. ROH was the first site to open and recruit for this trial, and I’m thrilled to see its early success.

Q: Looking ahead, what are your goals for your role in research development, and what areas of improvement or innovation are you most excited about?

CC: I hope to gain experience with a wider variety of studies, including device and pharmaceutical trials. One of the best things about working in research and development is the constant opportunity to learn and take on new challenges.

I also want to support the setup of more studies at ROH, enabling more clinicians and patients to engage in cutting-edge research that leads to better treatments and outcomes.

Above all, I hope every participant enjoys their research experience and feels encouraged to share it with others. By building a positive research culture, we can collectively advance healthcare and improve lives.